Series A · Biotech · Zurich, Switzerland · Founded 2018 · 51–200 employees
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company developing innovative bioconjugate vaccines using glycoengineering to combat antimicrobial resistance (AMR) and sexually transmitted infections like gonorrhea and chlamydia. Spin-off from GlycoVaxyn (acquired by GSK), it collaborates with GSK on Shigella vaccine (in-licensed) and has a pipeline including Staphylococcus aureus and Neisseria gonorrhoeae. Raised USD 37M (approx. EUR 34M) Series A in Oct 2023, extended to CHF 40M in 2024, advancing Phase 2 Shigella trial.
No open roles listed right now.